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For the future success of clinical hyperthermia in multimodal 
cancer therapy specifically in combination with radiotherapy 
a concentrated and coordinated effort in all domains is 
needed. Input must come from biology (e.g. 
thermoradiobiology, thermoimmunonology), medical physics 
(e.g. noninvasive thermometry, treatment planning), 
engineering (e.g. novel hardware for intensity modulated 
hyperthermia and image guided hyperthermia), IT (e.g. 
optimization and synergy of RT and HT-workflow); and clinics 
(phase I/II study in large animal with spontaneous tumors and 
for human patients with novel technology, 
multicenter/international randomized phase III studies for 
common tumours with stringent QA criteria). 
Key issues are: 
1.       Why, despite a sound thermoradiobiological rationale 
is clinical implementation of HT so slow?  
2.        Why is innovation and progress in the development of 
timely hardware and software technology so slow, 
specifically if compared to the recent progress in radiation 
oncology technology?  
3.       Why did hyperthermia not get a better integration into 
clinical protocols using state of the art radiation therapy 
technology?  
4.       What are the promises of thermoablative procedures 
like HIFU, RFA, or nanotechnology based hyperthermia 
compared to classical regional (capacitive or radiative) 
hyperthermia used as physical radio sensitizer? 
An international coordinated effort is needed with active 
participation of all stakeholders. Local institutional 
innovations are desperately needed from interested industrial 
partners, academic centers focusing on technology 
development and academic centers focusing on novel clinical 
trial design. This could provide optimal synergism and pave 
the way toward implementation of oncology hyperthermia as 
a standard treatment modality within multimodal cancer 
therapy. 
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Hyperthermia methods can be subdivided into local, 
locoregional and whole body heating, and in different 
temperature ranges either aiming for direct ablation 
(T>55°C, only for local heating) or for radiosensitization and 
chemosensitization (39°C<T<43°C, all three categories). The 
application of hyperthermia should always be guided by 
sufficient thermometry during treatment to ensure that the 
intended thermal dose is given to the entire target region. 
This is challenging due to tissue and blood flow 
heterogeneities which can affect the uniformity of the 
thermal dose distribution. 
Achieving a uniform temperature rise of 39-42°C is 
straightforward for whole body heating techniques, but more 
challenging for local and locoregional hyperthermia. Most 
clinical hyperthermia equipment uses radiofrequency (RF) 
and microwave (MW) antennas for local and locoregional 
heating of tumors. Deep seated tumors are heated with 
phased arrays of RF/MW antennas. The frequencies of 70-
150MHz used for heating deep seated tumors result in heating 
of the tumor and a large margin around the tumor. The trend 
is to increase both the frequency and the number of antennas 
in order to reduce the focus size and thus achieve more 
selective tumor heating. Temperature measurements are 
performed with a limited number of invasive temperature 
probes, these are now increasingly supplemented with non-
invasive temperature measurements using MRI and other 
techniques which yield a 3-D image of the temperature 
distribution. 
Tumor ablation is achieved with invasive interstitial RF, MW 
and ultrasound (US) techniques. A more recent non-invasive 
technique is High Intensity Focused Ultrasound (HIFU) 
combined with non-invasive MRI thermometry. HIFU is 
capable of focusing heating to regions <1cm, the use of HIFU 
to achieve uniform heating of a large region to 40-43°C is 
presently investigated.  
Reliable hyperthermia treatment planning is important for 
pre-treatment planning, adaptive planning during treatment 
and for reconstruction of the given thermal dose distribution 
after treatment. A challenge for hyperthermia treatment 
planning is to model both the energy absorption in the tissue 
and the bio heat transfer by tissue blood flow, and the latter 
may also change during treatment. The latest planning 
systems are capable of fast and high resolution computations, 
sufficiently fast for real time computation during treatment, 
e.g. to adapt settings in response to changing blood flow 
values. 
Conclusion: hyperthermia equipment is increasingly capable 
of providing a well-controlled dose distribution similar to 
standards in radiation oncology. This well-controlled dose 
distribution is essential in achieving optimal clinical results. 
    
SP-0300   
Hyperthermia combined with brachytherapy  
A. Chichel1 
1Greater Poland Cancer Centre, Department of 
Brachytherapy, Poznan, Poland  
 
Hyperthermia (HT) serves as a safe adjuvant treatment to 
radiotherapy in order to enhance its clinical results 
(radiosensitisation). It causes usually no or minimal injury to 
normal tissues. The best approach is to deliver hyperthermia 
and radiation simultaneously, which is difficult in common 
practice. The above is supported with extensive preclinical 
data and a number of randomized clinical trials concerning 
mainly combination of different types of hyperthermia 
treatment with standard external beam radiotherapy of 
specific types of cancer. Unfortunately, brachytherapy based 
HT treatment is quite poorly investigated and these data are 
scarce. Nevertheless, a short subjective literature review will 
be presented. Then, some possible clinical applications will 
be discussed, e.g. superficial or interstitial local/regional HT 
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combined with interstitial brachytherapy (clinical cases of 
breast cancer recurrence, recurrent melanoma, etc.). 
Contemporary sophisticated CT-based interstitial 
brachytherapy is based on multi-catheter implants piercing 
the tumor or its bed. The same set of elastic tubes can be 
successfully used for hyperthermia treatment. In this 
approach tiny microwave antennas along with thermometers 
(for temperature measurement and adjustments) are inserted 
into the treated volume via brachytherapy applicators. A set 
of CT scans used for treatment planning delivers strict 
geometrical information about 3D orientation of applicators 
within the CTV and enables the physician to plan the best 
pattern of antennas and thermometers to safely heat the 
target volume just before/after irradiation. Such an example 
of reproducible combination of interstitial BT with interstitial 
and superficial HT supported by CT-based treatment planning 
will be presented. 
Joint Symposium: ESTRO-JASTRO: Particle therapy state of 
the art  
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There are mainly four challenges in photon radiotherapy.  
1. Proximity to  critical organs
2. Tumor motion
3. Large tumor volume
4. Radio-resistance
 We have developed and used fiducial markers, four-
dimensional radiotherapy (4DRT) planning concept, and real-
time tumor-tracking radiotherapy (RTRT) system since 1999 
to overcome the first and second problem (Shirato, H. et al. 
Lancet 1999).  It was effective to treat small  tumors such as 
lung, liver, and prostate cancers effectively with the 
accuracy of ± 2 mm even with complex internal organ motion 
(Seppenwoolde, Y. et al. IJROBP 2002).  
We have development a new radiotherapy system with 
Hitachi co ltd  to cure large, moving tumors situated near 
critical organs. It is image-guided spot-scanning proton beam 
therapy system with real-time tumor-tracking system. Cone-
beam CT scan is availabe for precise set-up. Two sets of 
fluoroscope are mounted in the gantry, used for real-time 
tracking of fiducial marker near the tumor, and the proton 
beam is gated to treat large tumors with the accuracy of ± 2 
mm.  The system was approved by Japanese government in 
February 2014 and commercially available as PROBEAT-RT 
(Hitachi, co. ltd., Japan) .  We have been able to successfully 
reduce the size of the system, to make it small enough to be 
installed in the premises of hospitals, by dedicating to the 
spot-scanning Irradiation Technique.  Initial experience of 
this system will be presented.  
Clinical trial has been started since March 2014 for those 
patients who have gain in dose distribution comparing to 
photon therapy.  Acute adverse effects were evaluated and 
shown to be minimal in the initial 6 months. 
 SP-0302   
The heavier the better: protons vs carbons? 
J.Debus1 
1University Klinikum Heidelberg, Medical Physics, 
Heidelberg, Germany 
Abstract not received. 
SP-0303   
Twenty years experience of carbon ion radiotherapy at 
NIRS-HIMAC 
T. Kamada1 
1National Institute of Radiological Sciences (NIRS), Research 
Center for Charged Particle Therapy, Chiba, Japan  
(National Institute of Radiological Sciences) using HIMAC 
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world’s first heavy ion accelerator complex dedicated to 
medical use in a hospital environment. As of February 2014, a 
total of 8,931 patients were treated with carbon ion 
radiotherapy using HIMAC. The results have shown that 
carbon ion radiotherapy has the ability to provide a sufficient 
dose to the tumor without unacceptable morbidity in the 
surrounding normal tissues. Tumors that appear to respond 
favorably to carbon ions include locally advanced tumors and 
those with histologically non-squamous cell type of tumors 
such as adenocarcinoma, adenoid cystic carcinoma, 
malignant melanoma, hepatoma, and bone and soft tissue 
sarcomas. By using biological and physical properties of the 
high-LET carbon ion beams, the efficacy of treatment 
regimen with small fractions in shorter treatment course has 
been also confirmed for almost all type of tumors in our 
carbon ion radiotherapy experience. More than 10,000 
patients treated with carbon therapy worldwide, more than 
80% were treated at NIRS and other facilities in Japan. The 
current facilities and devices may be termed as first-
generation equipment. Making existing equipment smaller 
and less expensive is only the first step. It is be far from 
satisfactory for next-generation facility. One new technique 
that deserves attention as the next generation system is the 
spot scanning beam delivery and the compact 
superconducting magnet mounted rotating gantry. Spot 
scanning beam delivery is designed to treat the complex-
shaped lesions that are difficult targets for the by current 
techniques. Use of the rotating gantry will minimize the time 
for patient positioning and improve patient comfort. Owing 
to simplified treatment set-up procedures and reduced 
treatment time, more patients with poor performance status 
will be eligible for this therapy. We anticipate that the 
introduction of these innovations will not only improve the 
therapeutic outcome but also increase patient throughput. 
The new system will also eliminate the need for making 
compensation filters as well as patient-specific collimators. 
NIRS has finished the construction of the new facility's 
building and the installation of the beam delivery system for 
the pencil beam scanning. A clinical research using the pencil 
beam scanning was in operation with the original fully 
automated patient positioning system since May 2011. We 
could treat a total of almost 1000 patients in the FS year of 
2013 by the broad beam delivery and the pencil beam 
scanning. Good performance of this new carbon pencil beam 
delivery system has been confirmed at NIRS. Regarding the 
compact superconducting magnet mounted rotating gantry, 
the magnets for the gantry were already made and have been 
testing at NIRS successfully. The NIRS novel gantry system 
will be expected to be in operation in early 2016. 
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